Author worries TrumpRX's low-price GLP-1 offering threatens HIMS' value proposition and questions whether it can survive long enough to grow out of it.
HIMS — AVOID The author argues that with the announcement of TrumpRX, HIMS will be affected because low-price GLP-1 is quite literally their value proposition. The concern is whether HIMS can survive long enough to grow out of this competitive pressure. The author notes they already exited before the after-hours drop and is seeking more views.
With the announcement of TrumpRX, I feel that hims definitely will be affected as low price glp is quite literally their value proposition. The question is will they survive long enough to grow out of this.
This Reddit post, published February 07, 2026, features u/anonymous_sheep1 discussing HIMS. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/anonymous_sheep1 · Tickers: HIMS